A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

Condition:   Double Express Diffuse Large B-cell Lymphoma Intervention:   Drug: Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy Sponsor:   Sun Yat-sen University Not yet recruiting

Source: ClinicalTrials.gov - September 6, 2022 Category: Research Source Type: clinical trials